Image

Perimodiolar Implant Performance in Adults With Low-Frequency Residual Hearing

Perimodiolar Implant Performance in Adults With Low-Frequency Residual Hearing

Non Recruiting
18-69 years
All
Phase N/A

Powered by AI

Overview

The purpose of the feasibility study is to investigate hearing performance (audiometry and speech perception) using the CI632 in a group of adults (n=15) with low-frequency residual hearing who meet inclusion criteria.

Eligibility

Inclusion Criteria:

  1. 18 years-of-age or older at the time of surgery.
  2. Low-frequency threshold at 500 Hz ≤ 50 dB HL and high-frequency pure-tone average (PTA), 2000-8000 Hz ≥ 65 dB HL in the ear to be implanted.
  3. Pure-tone average (PTA) (0.5k, 1k, 2k Hz) > 30 dB HL in the contralateral ear.
  4. CNC word recognition scores (mean of two lists) ≤ 60% in the ear to be implanted and ≤ 80% in the contralateral ear.
  5. English spoken as a primary language.
  6. Willing and able to provide written informed consent.

Exclusion Criteria:

  1. Individuals greater than or equal to 70 years at the time of surgery.
  2. Duration of severe to profound sensorineural hearing loss > 20 years per self-report.
  3. Onset of sensorineural hearing loss, for the purpose of this study, prior to 5 years-of-age.
  4. Ossification or any other cochlear anomaly that might prevent complete insertion of the electrode array.
  5. Conductive overlay of 15 dB or greater at two or more frequencies, in the range of 250 through 1000 Hz in the ear to be implanted.
  6. Hearing loss of neural or central origin.
  7. Diagnosis of Auditory Neuropathy.
  8. Active middle-ear infection.
  9. Medical or psychological conditions that contraindicate undergoing surgery as determined by the Investigator.
  10. Unrealistic expectations on the part of the subject, regarding the possible benefits, risks, and limitations that are inherent to the device and/or procedure, as determined by the Investigator.
  11. Additional handicaps that would prevent or restrict participation in the audiological evaluations as determined by the Investigator.
  12. Unable or unwilling to comply with the requirements of the clinical investigation as determined by the Investigator.
  13. Investigator site personnel directly affiliated with this study and/or their immediate family (spouse, parent, child, or sibling).
  14. Cochlear employees or employees of a Contract Research Organization (CRO) or contractors engaged by Cochlear for the purposes of this investigation.
  15. Currently participating, or has participated in the last 30 days, in another interventional clinical investigation/trial involving an investigational drug or device.

Study details
    Sensorineural Hearing Loss
    Low-Frequency Residual Hearing

NCT04741009

Cochlear

20 August 2025

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.